Literature DB >> 1592469

Increased vascular angiotensin formation in female rats harboring the mouse Ren-2 gene.

K F Hilgers1, J Peters, R Veelken, M Sommer, G Rupprecht, D Ganten, F C Luft, J F Mann.   

Abstract

Rats harboring the mouse Ren-2 transgene develop hypertension despite low levels of plasma renin activity. We tested the hypothesis that these rats exhibit an increase in vascular angiotensin formation caused by the presence of the transgene. We measured the release of angiotensins I and II from isolated perfused hindquarters by high-performance liquid chromatography and radioimmunoassay. Female rats heterozygous for the transgene had significantly elevated mean arterial pressure compared with control rats (189.3 +/- 9.5 versus 110.0 +/- 5.4 mm Hg, p less than 0.05). Plasma angiotensin II was significantly decreased in transgenic rats. Transgenic rat hindquarters released more angiotensin I (121 +/- 37 versus 39 +/- 12 fmol/30 min, n = 7 each) and more angiotensin II (210 +/- 21 versus 62 +/- 12 fmol/30 min, p less than 0.05, n = 7 each) than control rat hindquarters. Captopril increased angiotensin I release and decreased angiotensin II values in both transgenic and control rat hindquarters. Bilateral nephrectomy 24 hours before hindquarter perfusion greatly reduced angiotensin release from control rat hindquarters but not from transgenic rat hind limbs. We also tested for the presence of Ren-2 messenger RNA in mesenteric and aortic tissue by RNase protection assay and Northern blot analysis. We found that Ren-2 messenger RNA was present in mesenteric and aortic tissue of transgenic but not of control rats. We conclude that the Ren-2 transgene is expressed in vascular tissue of transgenic rats and may be responsible for substantial increases in vascular angiotensin formation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592469     DOI: 10.1161/01.hyp.19.6.687

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver.

Authors:  M Véniant; J Ménard; P Bruneval; S Morley; M F Gonzales; J Mullins
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

2.  Cardiovascular responses to angiotensins I and II in normotensive and hypertensive rats; effects of NO synthase inhibition or ET receptor antagonism.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade.

Authors:  M Böhm; A Lippoldt; W Wienen; D Ganten; M Bader
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

4.  Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats.

Authors:  Virgínia S Lemos; Steyner F Côrtes; Denise M R Silva; Maria J Campagnole-Santos; Robson A S Santos
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

5.  Zona glomerulosa of the adrenal gland in a transgenic strain of rat: a morphologic and functional study.

Authors:  S Rocco; P Rebuffat; M Cimolato; G Opocher; J Peters; G Mazzocchi; D Ganten; F Mantero; G G Nussdorfer
Journal:  Cell Tissue Res       Date:  1994-10       Impact factor: 5.249

Review 6.  The renin-angiotensin system in transgenic rats.

Authors:  J Wagner; F Thiele; D Ganten
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

7.  Vitamin D depletion aggravates hypertension and target-organ damage.

Authors:  Louise Bjørkholt Andersen; Lukasz Przybyl; Nadine Haase; Frauke von Versen-Höynck; Fatimunnisa Qadri; Jan Stener Jørgensen; Grith Lykke Sorensen; Palle Fruekilde; Marko Poglitsch; István Szijarto; Maik Gollasch; Joerg Peters; Dominik N Muller; Henrik Thybo Christesen; Ralf Dechend
Journal:  J Am Heart Assoc       Date:  2015-01-28       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.